Fulminant Hepatitis Associated with Chronic Consumption of 3,4-Methylenedioxy-Methamphetamine; Case Report
- 1 Department of Internal Medicine, ISSSTE APP General Hospital of Tepic, Tepic, Nayarit, Mexico
- 2 Department of Internal Medicine, ISSSTE APP General Hospital of Tepic, Tepic, Nayarit, Mexico
- 3 Department of Internal Medicine, ISSSTE APP General Hospital of Tepic, Tepic, Nayarit, Mexico
- 4 Department of Internal Medicine, ISSSTE APP General Hospital of Tepic, Tepic, Nayarit, Mexico
- 5 Department of Internal Medicine, ISSSTE APP General Hospital of Tepic, Tepic, Nayarit, Mexico
- 6 Department of Internal Medicine, ISSSTE APP General Hospital of Tepic, Tepic, Nayarit, Mexico
- 7 Department of Internal Medicine, ISSSTE APP General Hospital of Tepic, Tepic, Nayarit, Mexico
Abstract
The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA), also called ecstasy, is a neurotoxin widely consumed among young people that has increased in recent years because it is a recreational drug, of which immediate effects are known such as a greater sensation of well-being, extroversion, increased sensory perception. However, its long-term effects have been described very little in the medical literature, including damage to the heart, central nervous system, kidney, etc. One of its little-known effects is hepatotoxicity, of which few cases are known associated with fulminant hepatitis, which is a rapidly deteriorating condition that is generally associated with a syndrome of multiple organ dysfunction and death. Therefore, it is very important to know this type of damage in the short and long term. The following case is of a 39-year-old man who came to our service due to jaundice syndrome and the only history of MDMA consumption, who as the days went by met the criteria for fulminant liver failure, with damage to multiple organs (organ dysfunction syndrome).
- Luethi, D. and Liechti, M.E. (2020) Designer Drugs: Mechanism of Action and Adverse Effects. Archives o f Toxicology , 94, 1085-1133. https://doi.org/10.1007/s00204-020-02693-7
- Christophersen, A.S. (2000) Amphetamine Designer Drugs—An Overview and Epidemiology. Toxicology Letters , 112-113, 127-131. https://doi.org/10.1016/S0378-4274(99)00205-2
- Campbell, G.A. and Rosner, M.H. (2008) The Agony of Ecstasy. Clinical Journal o f the American Society o f Nephrology , 3, 1852-1860. https://doi.org/10.2215/CJN.02080508
- Colado, M.I. (2008) Éxtasis (MDMA) y drogas de diseño: estructura, farmacología, mecanismos de acción y efectos en el ser humano. Trastornos Adictivos , 10, 175-182. https://doi.org/10.1016/S1575-0973(08)76364-5
- Montiel-Duarte, C., Varela–Rey, M., Oses-Prieto, J., López-Zabalza, M.J., Beitia, G., Cenarruzabeitia, E. and Iraburu, M.J. (2002) 3,4-Methylenedioxymethamphetamine (“Ecstasy”) Induces Apoptosis of Cultured Rat Liver Cells. Biochimica e t Biophysica Acta ( BBA )— Molecular Basis o f Disease , 1588, 26-32. https://doi.org/10.1016/S0925-4439(02)00112-6
- Jones, A.L. and Simpson, K.J. (1999) Review Article: Mechanisms and Management of Hepatotoxicity in Ecstasy (MDMA) and Amphetamine Intoxications. Alimentary Pharmacology & Therapeutics , 13, 129-133. https://doi.org/10.1046/j.1365-2036.1999.00454.x
- Shingina, A., Mukhtar, N.A., Wakim-Fleming, J., Alqahtani, S.A., Wong, R.J., Limketkai, B.N., Larson, A.M. and Grant, L. (2023) Acute Liver Failure Guidelines. The American Journal of Gastroenterology , 118, 1128-1153. https://doi.org/10.14309/ajg.0000000000002340
- O’Grady, J., Schalm, S.W. and Williams, R. (1993) Acute Liver Failure: Redefining the Syndromes. The Lancet , 342, 273-275. https://doi.org/10.1016/0140-6736(93)91818-7
- Peck, J., Replete, N., Melquist, S.J., Flores, F. and Wilsey, M. (2020) Adolescent with Acute Liver Failure in the Setting of Ethanol, Cocaine, and Ecstasy Ingestion Treated with a Molecular Adsorbent Recirculating System. Cureus. https://doi.org/10.7759/cureus.9699